Dr Michelle Fitzmaurice

Postdoctoral Fellow
  • PhD, Clinical Biochemistry
    Ulster University, United Kingdom

  • BSc (Hons), Human Nutrition
    Ulster University, United Kingdom

Medicine & Health
School of Clinical Medicine

Dr Michelle Fitzmaurice is a translational researcher specialising in metabolic signalling and glycation biology, with a focus on clinically relevant biomarker development.

Her research examines how metabolic and hormonal signals are modified across biological systems, and how early molecular changes contribute to disease risk and progression. She integrates endocrinology, glycation biology and microbiome science to investigate how post-translational modifications and metabolic interactions influence health across the lifespan.

Her work centres on developing analytically robust, clinically implementable biomarkers using routinely collected biospecimens and well-characterised patient cohorts, with applications in pregnancy, metabolic disease, neurodegeneration and healthy ageing.

Dr Fitzmaurice is based within the Microbiome Research Centre, St George campus, School of Clinical Medicine, and holds cross-appointments supporting translational research, ethics and governance across hospital and university environments.

Mobile
+61452196332
Phone
+61 2 9348 0691
Location
UNSW Microbiome Research Centre St George & Sutherland Clinical Campuses, UNSW Medicine Level 2, Pitney Building, St George Hospital Kogarah UNSW SYDNEY 2052
  • Journal articles | 2024
    Cui C; Jiang X; Fitzmaurice M; El-Omar E, 2024, 'A Healthy Optimal Australian Microbiome sub-study: oral and gut microbiome dysbiosis in obesity is associated with reduced beneficial taxa', Obesity Research & Clinical Practice, 18, pp. S7 - S7, http://dx.doi.org/10.1016/j.orcp.2024.09.017
    Journal articles | 2024
    Yip E; Fitzmaurice M; DeVroome M; Nicholl M, 2024, 'Skin to skin and breastfeeding in theatre: A Clinical Audit', WOMEN AND BIRTH, 37, pp. 41 - 41, http://dx.doi.org/10.1016/j.wombi.2024.101782

Dr Fitzmaurice has been awarded competitive research funding to support translational investigations into metabolic signalling, biomarker development, and host–microbiome interactions.

  • Competitive philanthropic research grant (2024; $50,000)
    Funding supported the characterisation of glycated peptide biomarkers and the development of translational diagnostic approaches using clinical biospecimens, leveraging established research infrastructure.

  • Dementia Research Community Grant (2024; $79,994)
    Funding supported a translational microbiome and biomarker study nested within the Healthy Optimal Australian Microbiome (HOAM) program, examining early molecular changes associated with dementia and healthy ageing using well-characterised clinical cohorts.

  • Competitive research grant (2024; $500,000)
    Funding supported translational research investigating metabolic signalling and early disease trajectories within a broader multi-system research program.

  • Microbiome Research Centre Director’s Award for Research Excellence (2023)

  • PhD Scholarship, Department of Education and Learning, Northern Ireland

Dr Fitzmaurice’s research activities focus on understanding how metabolic and hormonal signals are modified across biological systems, and how early molecular changes influence disease risk and progression. Her work centres on mechanistic investigation, biomarker development and translational application using clinical biospecimens.

Her current research activities include:

  • Characterising glycated hormones and peptides to determine how post-translational modifications alter biological signalling and metabolic responses
  • Investigating host–microbiome metabolic interactions and their role in shaping endocrine and inflammatory pathways
  • Identifying early biomarkers of metabolic dysfunction using routinely collected clinical samples and well-characterised patient cohorts
  • Integrating biochemical and multi-omic data to examine early disease progression and identify opportunities for intervention
  • Developing and validating diagnostic pipelines that are analytically robust and clinically implementable

These activities are undertaken in close collaboration with clinicians, laboratory scientists and industry partners, with the aim of strengthening early detection strategies and improving clinical decision-making.